[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$faM9b1nhKZACUJ-JaVSx0Oj6tlmn07qQyu-95MUOQpCg":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":9,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":30,"phaseBuckets":36,"rows":43},"Louisiana State University Health Sciences Center Shreveport",[4],42,false,5,2,3249,24,[13,16,18,20,22,24,26,28],{"name":14,"count":15},"Schizophrenia",3,{"name":17,"count":15},"Movement, Abnormal",{"name":19,"count":15},"Lower Extremity Problem",{"name":21,"count":15},"Mild Cognitive Impairment",{"name":23,"count":9},"Breast Cancer",{"name":25,"count":9},"Schizoaffective Disorder",{"name":27,"count":9},"Colorectal Cancer",{"name":29,"count":9},"Osteoarthritis, Knee",[31],{"nctId":32,"briefTitle":33,"date":34,"intervention":35},"NCT06482554","Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.","2026-12","Lumateperone 42 mg",[37,38,39,40,41,42],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[44,70,88,115,143,188,235,257,275,293,311,329,347,365,383,401,419,446,471,489,507,525,543,566,589,616,634,652,682,707,730],{"intervention":35,"totalTrials":45,"cells":46},1,{"EARLY_PHASE1":47,"PHASE1":50,"PHASE2":52,"PHASE3":54,"PHASE4":66,"NA":68},{"trials":48,"activeCount":49},[],0,{"trials":51,"activeCount":49},[],{"trials":53,"activeCount":49},[],{"trials":55,"activeCount":45,"soonestReadout":34},[56],{"nctId":32,"briefTitle":33,"status":57,"phases":58,"primaryCompletion":34,"completion":34,"start":59,"enrollment":60,"conditions":61,"interventions":64},"RECRUITING",[40],"2024-06",80,[62,14,63],"Apathy","Schizophrenia; Psychosis",[35,65],"Risperidone 2 mg",{"trials":67,"activeCount":49},[],{"trials":69,"activeCount":49},[],{"intervention":65,"totalTrials":45,"cells":71},{"EARLY_PHASE1":72,"PHASE1":74,"PHASE2":76,"PHASE3":78,"PHASE4":84,"NA":86},{"trials":73,"activeCount":49},[],{"trials":75,"activeCount":49},[],{"trials":77,"activeCount":49},[],{"trials":79,"activeCount":45,"soonestReadout":34},[80],{"nctId":32,"briefTitle":33,"status":57,"phases":81,"primaryCompletion":34,"completion":34,"start":59,"enrollment":60,"conditions":82,"interventions":83},[40],[62,14,63],[35,65],{"trials":85,"activeCount":49},[],{"trials":87,"activeCount":49},[],{"intervention":89,"totalTrials":45,"cells":90},"Interferon beta 1a, oral doxycycline",{"EARLY_PHASE1":91,"PHASE1":93,"PHASE2":95,"PHASE3":97,"PHASE4":99,"NA":113},{"trials":92,"activeCount":49},[],{"trials":94,"activeCount":49},[],{"trials":96,"activeCount":49},[],{"trials":98,"activeCount":49},[],{"trials":100,"activeCount":49},[101],{"nctId":102,"briefTitle":103,"status":104,"phases":105,"primaryCompletion":106,"completion":107,"start":108,"enrollment":109,"conditions":110,"interventions":112},"NCT00246324","Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis","COMPLETED",[41],"2009-08","2009-10","2003-12",16,[111],"Multiple Sclerosis",[89],{"trials":114,"activeCount":49},[],{"intervention":116,"totalTrials":45,"cells":117},"ICG",{"EARLY_PHASE1":118,"PHASE1":120,"PHASE2":122,"PHASE3":124,"PHASE4":139,"NA":141},{"trials":119,"activeCount":49},[],{"trials":121,"activeCount":49},[],{"trials":123,"activeCount":49},[],{"trials":125,"activeCount":49},[126],{"nctId":127,"briefTitle":128,"status":129,"phases":130,"primaryCompletion":131,"completion":131,"start":132,"enrollment":133,"conditions":134,"interventions":138},"NCT01693484","Application of Indocyanine Green Angiography for Closed Operative Calcaneus Fractures","TERMINATED",[39,40],"2015-03","2013-04",13,[135,136,137],"Fractures, Comminuted","Surgical Wound Dehiscence","Necrosis",[116],{"trials":140,"activeCount":49},[],{"trials":142,"activeCount":49},[],{"intervention":144,"totalTrials":15,"cells":145},"Polyphenon E",{"EARLY_PHASE1":146,"PHASE1":148,"PHASE2":161,"PHASE3":182,"PHASE4":184,"NA":186},{"trials":147,"activeCount":49},[],{"trials":149,"activeCount":49},[150],{"nctId":151,"briefTitle":152,"status":129,"phases":153,"primaryCompletion":154,"completion":154,"start":155,"enrollment":156,"conditions":157,"interventions":159},"NCT00707252","Study of Polyphenon E in Addition to Erlotinib in Advanced Non Small Cell Lung Cancer",[38],"2012-11","2008-01",11,[158],"Non-Small Cell Lung Cancer",[144,160],"Tarceva",{"trials":162,"activeCount":49},[163,173],{"nctId":164,"briefTitle":165,"status":104,"phases":166,"primaryCompletion":167,"completion":168,"start":169,"enrollment":170,"conditions":171,"interventions":172},"NCT00676793","A Study of the Effect of Polyphenon E (Green Tea Extract) on Breast Cancer Progression",[39],"2009-12","2013-07","2004-05",32,[23],[144],{"nctId":174,"briefTitle":175,"status":104,"phases":176,"primaryCompletion":177,"completion":177,"start":169,"enrollment":178,"conditions":179,"interventions":181},"NCT00676780","Green Tea Extract and Prostate Cancer",[39],"2008-12",33,[180],"Prostate Cancer",[144],{"trials":183,"activeCount":49},[],{"trials":185,"activeCount":49},[],{"trials":187,"activeCount":49},[],{"intervention":189,"totalTrials":9,"cells":190},"filgrastim",{"EARLY_PHASE1":191,"PHASE1":193,"PHASE2":209,"PHASE3":229,"PHASE4":231,"NA":233},{"trials":192,"activeCount":49},[],{"trials":194,"activeCount":49},[195],{"nctId":196,"briefTitle":197,"status":129,"phases":198,"primaryCompletion":199,"completion":199,"start":200,"enrollment":201,"conditions":202,"interventions":204},"NCT00003060","Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Metastatic Melanoma",[38],"2001-02-22","1995-03",6,[203],"Melanoma (Skin)",[189,205,206,207,208],"busulfan","cyclophosphamide","cyclosporine","methotrexate",{"trials":210,"activeCount":49},[211],{"nctId":212,"briefTitle":213,"status":129,"phases":214,"primaryCompletion":215,"completion":215,"start":216,"enrollment":217,"conditions":218,"interventions":219},"NCT00003086","Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer",[38,39],"2001-01-28","1997-03",12,[23],[189,220,221,222,206,223,224,225,226,227,228],"CAF regimen","carboplatin","cisplatin","doxorubicin hydrochloride","fluorouracil","ifosfamide","melphalan","paclitaxel","thiotepa",{"trials":230,"activeCount":49},[],{"trials":232,"activeCount":49},[],{"trials":234,"activeCount":49},[],{"intervention":206,"totalTrials":9,"cells":236},{"EARLY_PHASE1":237,"PHASE1":239,"PHASE2":245,"PHASE3":251,"PHASE4":253,"NA":255},{"trials":238,"activeCount":49},[],{"trials":240,"activeCount":49},[241],{"nctId":196,"briefTitle":197,"status":129,"phases":242,"primaryCompletion":199,"completion":199,"start":200,"enrollment":201,"conditions":243,"interventions":244},[38],[203],[189,205,206,207,208],{"trials":246,"activeCount":49},[247],{"nctId":212,"briefTitle":213,"status":129,"phases":248,"primaryCompletion":215,"completion":215,"start":216,"enrollment":217,"conditions":249,"interventions":250},[38,39],[23],[189,220,221,222,206,223,224,225,226,227,228],{"trials":252,"activeCount":49},[],{"trials":254,"activeCount":49},[],{"trials":256,"activeCount":49},[],{"intervention":220,"totalTrials":45,"cells":258},{"EARLY_PHASE1":259,"PHASE1":261,"PHASE2":263,"PHASE3":269,"PHASE4":271,"NA":273},{"trials":260,"activeCount":49},[],{"trials":262,"activeCount":49},[],{"trials":264,"activeCount":49},[265],{"nctId":212,"briefTitle":213,"status":129,"phases":266,"primaryCompletion":215,"completion":215,"start":216,"enrollment":217,"conditions":267,"interventions":268},[38,39],[23],[189,220,221,222,206,223,224,225,226,227,228],{"trials":270,"activeCount":49},[],{"trials":272,"activeCount":49},[],{"trials":274,"activeCount":49},[],{"intervention":221,"totalTrials":45,"cells":276},{"EARLY_PHASE1":277,"PHASE1":279,"PHASE2":281,"PHASE3":287,"PHASE4":289,"NA":291},{"trials":278,"activeCount":49},[],{"trials":280,"activeCount":49},[],{"trials":282,"activeCount":49},[283],{"nctId":212,"briefTitle":213,"status":129,"phases":284,"primaryCompletion":215,"completion":215,"start":216,"enrollment":217,"conditions":285,"interventions":286},[38,39],[23],[189,220,221,222,206,223,224,225,226,227,228],{"trials":288,"activeCount":49},[],{"trials":290,"activeCount":49},[],{"trials":292,"activeCount":49},[],{"intervention":222,"totalTrials":45,"cells":294},{"EARLY_PHASE1":295,"PHASE1":297,"PHASE2":299,"PHASE3":305,"PHASE4":307,"NA":309},{"trials":296,"activeCount":49},[],{"trials":298,"activeCount":49},[],{"trials":300,"activeCount":49},[301],{"nctId":212,"briefTitle":213,"status":129,"phases":302,"primaryCompletion":215,"completion":215,"start":216,"enrollment":217,"conditions":303,"interventions":304},[38,39],[23],[189,220,221,222,206,223,224,225,226,227,228],{"trials":306,"activeCount":49},[],{"trials":308,"activeCount":49},[],{"trials":310,"activeCount":49},[],{"intervention":223,"totalTrials":45,"cells":312},{"EARLY_PHASE1":313,"PHASE1":315,"PHASE2":317,"PHASE3":323,"PHASE4":325,"NA":327},{"trials":314,"activeCount":49},[],{"trials":316,"activeCount":49},[],{"trials":318,"activeCount":49},[319],{"nctId":212,"briefTitle":213,"status":129,"phases":320,"primaryCompletion":215,"completion":215,"start":216,"enrollment":217,"conditions":321,"interventions":322},[38,39],[23],[189,220,221,222,206,223,224,225,226,227,228],{"trials":324,"activeCount":49},[],{"trials":326,"activeCount":49},[],{"trials":328,"activeCount":49},[],{"intervention":224,"totalTrials":45,"cells":330},{"EARLY_PHASE1":331,"PHASE1":333,"PHASE2":335,"PHASE3":341,"PHASE4":343,"NA":345},{"trials":332,"activeCount":49},[],{"trials":334,"activeCount":49},[],{"trials":336,"activeCount":49},[337],{"nctId":212,"briefTitle":213,"status":129,"phases":338,"primaryCompletion":215,"completion":215,"start":216,"enrollment":217,"conditions":339,"interventions":340},[38,39],[23],[189,220,221,222,206,223,224,225,226,227,228],{"trials":342,"activeCount":49},[],{"trials":344,"activeCount":49},[],{"trials":346,"activeCount":49},[],{"intervention":225,"totalTrials":45,"cells":348},{"EARLY_PHASE1":349,"PHASE1":351,"PHASE2":353,"PHASE3":359,"PHASE4":361,"NA":363},{"trials":350,"activeCount":49},[],{"trials":352,"activeCount":49},[],{"trials":354,"activeCount":49},[355],{"nctId":212,"briefTitle":213,"status":129,"phases":356,"primaryCompletion":215,"completion":215,"start":216,"enrollment":217,"conditions":357,"interventions":358},[38,39],[23],[189,220,221,222,206,223,224,225,226,227,228],{"trials":360,"activeCount":49},[],{"trials":362,"activeCount":49},[],{"trials":364,"activeCount":49},[],{"intervention":226,"totalTrials":45,"cells":366},{"EARLY_PHASE1":367,"PHASE1":369,"PHASE2":371,"PHASE3":377,"PHASE4":379,"NA":381},{"trials":368,"activeCount":49},[],{"trials":370,"activeCount":49},[],{"trials":372,"activeCount":49},[373],{"nctId":212,"briefTitle":213,"status":129,"phases":374,"primaryCompletion":215,"completion":215,"start":216,"enrollment":217,"conditions":375,"interventions":376},[38,39],[23],[189,220,221,222,206,223,224,225,226,227,228],{"trials":378,"activeCount":49},[],{"trials":380,"activeCount":49},[],{"trials":382,"activeCount":49},[],{"intervention":227,"totalTrials":45,"cells":384},{"EARLY_PHASE1":385,"PHASE1":387,"PHASE2":389,"PHASE3":395,"PHASE4":397,"NA":399},{"trials":386,"activeCount":49},[],{"trials":388,"activeCount":49},[],{"trials":390,"activeCount":49},[391],{"nctId":212,"briefTitle":213,"status":129,"phases":392,"primaryCompletion":215,"completion":215,"start":216,"enrollment":217,"conditions":393,"interventions":394},[38,39],[23],[189,220,221,222,206,223,224,225,226,227,228],{"trials":396,"activeCount":49},[],{"trials":398,"activeCount":49},[],{"trials":400,"activeCount":49},[],{"intervention":228,"totalTrials":45,"cells":402},{"EARLY_PHASE1":403,"PHASE1":405,"PHASE2":407,"PHASE3":413,"PHASE4":415,"NA":417},{"trials":404,"activeCount":49},[],{"trials":406,"activeCount":49},[],{"trials":408,"activeCount":49},[409],{"nctId":212,"briefTitle":213,"status":129,"phases":410,"primaryCompletion":215,"completion":215,"start":216,"enrollment":217,"conditions":411,"interventions":412},[38,39],[23],[189,220,221,222,206,223,224,225,226,227,228],{"trials":414,"activeCount":49},[],{"trials":416,"activeCount":49},[],{"trials":418,"activeCount":49},[],{"intervention":420,"totalTrials":45,"cells":421},"MTD of Velcade, Nipent and Rituxan established in Part 1",{"EARLY_PHASE1":422,"PHASE1":424,"PHASE2":426,"PHASE3":440,"PHASE4":442,"NA":444},{"trials":423,"activeCount":49},[],{"trials":425,"activeCount":49},[],{"trials":427,"activeCount":49},[428],{"nctId":429,"briefTitle":430,"status":431,"phases":432,"primaryCompletion":433,"completion":433,"start":434,"enrollment":49,"conditions":435,"interventions":439},"NCT01460602","Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma","WITHDRAWN",[38,39],"2014-10","2010-05",[436,437,438],"Follicular Lymphoma","Marginal Zone Lymphoma","Mantle Cell Lymphoma",[420],{"trials":441,"activeCount":49},[],{"trials":443,"activeCount":49},[],{"trials":445,"activeCount":49},[],{"intervention":447,"totalTrials":45,"cells":448},"Cetuximab",{"EARLY_PHASE1":449,"PHASE1":451,"PHASE2":453,"PHASE3":465,"PHASE4":467,"NA":469},{"trials":450,"activeCount":49},[],{"trials":452,"activeCount":49},[],{"trials":454,"activeCount":49},[455],{"nctId":456,"briefTitle":457,"status":129,"phases":458,"primaryCompletion":459,"completion":459,"start":460,"enrollment":461,"conditions":462,"interventions":464},"NCT01326923","Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer",[39],"2014-02","2010-06",7,[463],"Head and Neck Squamous Cell Cancer",[447],{"trials":466,"activeCount":49},[],{"trials":468,"activeCount":49},[],{"trials":470,"activeCount":49},[],{"intervention":160,"totalTrials":45,"cells":472},{"EARLY_PHASE1":473,"PHASE1":475,"PHASE2":481,"PHASE3":483,"PHASE4":485,"NA":487},{"trials":474,"activeCount":49},[],{"trials":476,"activeCount":49},[477],{"nctId":151,"briefTitle":152,"status":129,"phases":478,"primaryCompletion":154,"completion":154,"start":155,"enrollment":156,"conditions":479,"interventions":480},[38],[158],[144,160],{"trials":482,"activeCount":49},[],{"trials":484,"activeCount":49},[],{"trials":486,"activeCount":49},[],{"trials":488,"activeCount":49},[],{"intervention":205,"totalTrials":45,"cells":490},{"EARLY_PHASE1":491,"PHASE1":493,"PHASE2":499,"PHASE3":501,"PHASE4":503,"NA":505},{"trials":492,"activeCount":49},[],{"trials":494,"activeCount":49},[495],{"nctId":196,"briefTitle":197,"status":129,"phases":496,"primaryCompletion":199,"completion":199,"start":200,"enrollment":201,"conditions":497,"interventions":498},[38],[203],[189,205,206,207,208],{"trials":500,"activeCount":49},[],{"trials":502,"activeCount":49},[],{"trials":504,"activeCount":49},[],{"trials":506,"activeCount":49},[],{"intervention":207,"totalTrials":45,"cells":508},{"EARLY_PHASE1":509,"PHASE1":511,"PHASE2":517,"PHASE3":519,"PHASE4":521,"NA":523},{"trials":510,"activeCount":49},[],{"trials":512,"activeCount":49},[513],{"nctId":196,"briefTitle":197,"status":129,"phases":514,"primaryCompletion":199,"completion":199,"start":200,"enrollment":201,"conditions":515,"interventions":516},[38],[203],[189,205,206,207,208],{"trials":518,"activeCount":49},[],{"trials":520,"activeCount":49},[],{"trials":522,"activeCount":49},[],{"trials":524,"activeCount":49},[],{"intervention":208,"totalTrials":45,"cells":526},{"EARLY_PHASE1":527,"PHASE1":529,"PHASE2":535,"PHASE3":537,"PHASE4":539,"NA":541},{"trials":528,"activeCount":49},[],{"trials":530,"activeCount":49},[531],{"nctId":196,"briefTitle":197,"status":129,"phases":532,"primaryCompletion":199,"completion":199,"start":200,"enrollment":201,"conditions":533,"interventions":534},[38],[203],[189,205,206,207,208],{"trials":536,"activeCount":49},[],{"trials":538,"activeCount":49},[],{"trials":540,"activeCount":49},[],{"trials":542,"activeCount":49},[],{"intervention":544,"totalTrials":45,"cells":545},"Cannabidiol",{"EARLY_PHASE1":546,"PHASE1":548,"PHASE2":558,"PHASE3":560,"PHASE4":562,"NA":564},{"trials":547,"activeCount":49},[],{"trials":549,"activeCount":49},[550],{"nctId":551,"briefTitle":552,"status":431,"phases":553,"primaryCompletion":554,"completion":554,"start":554,"enrollment":49,"conditions":555,"interventions":557},"NCT05002114","Evaluation of a Specific Transdermal Cannabidiol Product for Chronic Musculoskeletal Joint Pain.",[38],"2023-01",[556],"Musculoskeletal Joint Pain",[544],{"trials":559,"activeCount":49},[],{"trials":561,"activeCount":49},[],{"trials":563,"activeCount":49},[],{"trials":565,"activeCount":49},[],{"intervention":567,"totalTrials":45,"cells":568},"Microgranular Curcumin C3 Complex®",{"EARLY_PHASE1":569,"PHASE1":579,"PHASE2":581,"PHASE3":583,"PHASE4":585,"NA":587},{"trials":570,"activeCount":49},[571],{"nctId":572,"briefTitle":573,"status":104,"phases":574,"primaryCompletion":575,"completion":575,"start":460,"enrollment":178,"conditions":576,"interventions":578},"NCT01160302","Curcumin Biomarker Trial in Head and Neck Cancer",[37],"2016-01",[577],"Head and Neck Cancer",[567],{"trials":580,"activeCount":49},[],{"trials":582,"activeCount":49},[],{"trials":584,"activeCount":49},[],{"trials":586,"activeCount":49},[],{"trials":588,"activeCount":49},[],{"intervention":590,"totalTrials":45,"cells":591},"Vitamin D",{"EARLY_PHASE1":592,"PHASE1":606,"PHASE2":608,"PHASE3":610,"PHASE4":612,"NA":614},{"trials":593,"activeCount":49},[594],{"nctId":595,"briefTitle":596,"status":104,"phases":597,"primaryCompletion":598,"completion":598,"start":599,"enrollment":600,"conditions":601,"interventions":603},"NCT04939792","Optimization of Blood Levels of 25(OH)-Vitamin D in African Americans",[37],"2022-10-31","2020-11-06",165,[602],"Vitamin D Deficiency",[590,604,605],"Vitamin D + L-cysteine","L-cysteine",{"trials":607,"activeCount":49},[],{"trials":609,"activeCount":49},[],{"trials":611,"activeCount":49},[],{"trials":613,"activeCount":49},[],{"trials":615,"activeCount":49},[],{"intervention":604,"totalTrials":45,"cells":617},{"EARLY_PHASE1":618,"PHASE1":624,"PHASE2":626,"PHASE3":628,"PHASE4":630,"NA":632},{"trials":619,"activeCount":49},[620],{"nctId":595,"briefTitle":596,"status":104,"phases":621,"primaryCompletion":598,"completion":598,"start":599,"enrollment":600,"conditions":622,"interventions":623},[37],[602],[590,604,605],{"trials":625,"activeCount":49},[],{"trials":627,"activeCount":49},[],{"trials":629,"activeCount":49},[],{"trials":631,"activeCount":49},[],{"trials":633,"activeCount":49},[],{"intervention":605,"totalTrials":45,"cells":635},{"EARLY_PHASE1":636,"PHASE1":642,"PHASE2":644,"PHASE3":646,"PHASE4":648,"NA":650},{"trials":637,"activeCount":49},[638],{"nctId":595,"briefTitle":596,"status":104,"phases":639,"primaryCompletion":598,"completion":598,"start":599,"enrollment":600,"conditions":640,"interventions":641},[37],[602],[590,604,605],{"trials":643,"activeCount":49},[],{"trials":645,"activeCount":49},[],{"trials":647,"activeCount":49},[],{"trials":649,"activeCount":49},[],{"trials":651,"activeCount":49},[],{"intervention":653,"totalTrials":9,"cells":654},"aripiprazole",{"EARLY_PHASE1":655,"PHASE1":657,"PHASE2":659,"PHASE3":661,"PHASE4":663,"NA":665},{"trials":656,"activeCount":49},[],{"trials":658,"activeCount":49},[],{"trials":660,"activeCount":49},[],{"trials":662,"activeCount":49},[],{"trials":664,"activeCount":49},[],{"trials":666,"activeCount":49},[667,676],{"nctId":668,"briefTitle":669,"status":129,"phases":670,"primaryCompletion":671,"completion":671,"start":672,"enrollment":673,"conditions":674,"interventions":675},"NCT00211302","Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (BMS)",[42],"2006-02","2003-08",8,[14,25],[653],{"nctId":677,"briefTitle":678,"status":129,"phases":679,"primaryCompletion":671,"completion":671,"start":672,"enrollment":673,"conditions":680,"interventions":681},"NCT00211380","Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (SFBRI)",[42],[14,25],[653],{"intervention":683,"totalTrials":45,"cells":684},"chromium niacinate",{"EARLY_PHASE1":685,"PHASE1":687,"PHASE2":689,"PHASE3":691,"PHASE4":693,"NA":695},{"trials":686,"activeCount":49},[],{"trials":688,"activeCount":49},[],{"trials":690,"activeCount":49},[],{"trials":692,"activeCount":49},[],{"trials":694,"activeCount":49},[],{"trials":696,"activeCount":49},[697],{"nctId":698,"briefTitle":699,"status":104,"phases":700,"primaryCompletion":701,"completion":701,"start":702,"enrollment":703,"conditions":704,"interventions":706},"NCT01709123","Effects of Micronutrient (Chromium) Supplementation on Diabetes",[42],"2013-09","2007-08",62,[705],"Diabetes Mellitus, Type 1",[683],{"intervention":708,"totalTrials":45,"cells":709},"Insulin LISPRO",{"EARLY_PHASE1":710,"PHASE1":712,"PHASE2":714,"PHASE3":716,"PHASE4":718,"NA":720},{"trials":711,"activeCount":49},[],{"trials":713,"activeCount":49},[],{"trials":715,"activeCount":49},[],{"trials":717,"activeCount":49},[],{"trials":719,"activeCount":49},[],{"trials":721,"activeCount":49},[722],{"nctId":723,"briefTitle":724,"status":431,"phases":725,"primaryCompletion":726,"completion":726,"start":701,"enrollment":49,"conditions":727,"interventions":729},"NCT01636596","Efficacy of Pulsatile IV Insulin on Cognition and Amyloid Burden in Patients With Alzheimer's Disease",[42],"2015-01",[728,21],"Alzheimer's Disease",[708],{"intervention":731,"totalTrials":45,"cells":732},"Collagenase Ointment",{"EARLY_PHASE1":733,"PHASE1":735,"PHASE2":737,"PHASE3":739,"PHASE4":741,"NA":743},{"trials":734,"activeCount":49},[],{"trials":736,"activeCount":49},[],{"trials":738,"activeCount":49},[],{"trials":740,"activeCount":49},[],{"trials":742,"activeCount":49},[],{"trials":744,"activeCount":49},[745],{"nctId":746,"briefTitle":747,"status":129,"phases":748,"primaryCompletion":749,"completion":749,"start":460,"enrollment":9,"conditions":750,"interventions":753},"NCT01208220","Effectiveness Study of Santyl Ointment to Treat Pressure Ulcers",[42],"2011-12",[751,752],"Pressure Ulcer","Soft Tissue Necrosis Lower Limb",[731]]